Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B‐Cell Lymphoma treated with the<scp>AIEOP LNH</scp>‐97 protocol

Pillon, Marta; Mussolin, Lara; Carraro, Elisa; Conter, Valentino; Vinti, Luciana; Garaventa, Alberto; Piglione, Matilde; Buffardi, Salvatore; Sala, Alessandra; Santoro, Nicola; Nigro, Luca Lo; Mura, Rossella; Tondo, Annalisa; Casale, Fiorina; Farruggia, Piero; Pierani, Paolo; Cesaro, Simone; dʼAmore, Emanuele S.G.; Basso, Giuseppe

doi:10.1111/bjh.14240

Cited by 38 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in a larger study including 422 patients (379 BL), in the subgroup of 128 children and adolescents who had the study done, MDD was the only risk factor in multivariate analysis. Studies from the Children’s Oncology Group yielded nearly similar results 54. A report on 14 BL subjects showed that none of 12 MRD-negative after 2 months of therapy relapsed compared to both those found MRD-positive 55.…”

Section: Minimal Disseminated and Residual Diseasementioning

confidence: 77%

“…Apart from stage, these were an elevated LDH, primary mediastinal involvement, and combined bone marrow/CNS disease 37. The pediatric Italian review on 379 BL patients confirmed LDH to exert the greatest prognostic relevance ( P <0.0001) 54. Among biomarkers, apart from MDD/MRD which is not always available, some specific cytogenetic findings, such as deletion of 13q, gain of 7q, and complex cytogenetics, could impart a worse prognosis and/or benefit from treatment intensification 37.…”

Section: Other Clinical and Biological Risk Factorsmentioning

confidence: 97%

See 1 more Smart Citation

Burkitt lymphoma in adolescents and young adults: management challenges

Dozzo¹,

Carobolante²,

Donisi³

et al. 2016

AHMT

View full text Add to dashboard Cite

About one-half of all Burkitt lymphoma (BL) patients are younger than 40 years, and one-third belong to the adolescent and young adult (AYA) subset, defined by an age between 15 and 25–40 years, based on selection criteria used in different reports. BL is an aggressive B-cell neoplasm displaying highly characteristic clinico-diagnostic features, the biologic hallmark of which is a translocation involving immunoglobulin and c-MYC genes. It presents as sporadic, endemic, or epidemic disease. Endemicity is pathogenetically linked to an imbalance of the immune system which occurs in African children infected by malaria parasites and Epstein–Barr virus, while the epidemic form strictly follows the pattern of infection by HIV. BL shows propensity to extranodal involvement of abdominal organs, bone marrow, and central nervous system, and can cause severe metabolic and renal impairment. Nevertheless, BL is highly responsive to specifically designed short-intensive, rotational multiagent chemotherapy programs, empowered by the anti-CD20 monoclonal antibody rituximab. When carefully applied with appropriate supportive measures, these modern programs achieve a cure rate of approximately 90% in the average AYA patient, irrespective of clinical stage, which is the best result achievable in any aggressive lymphoid malignancy to date. The challenges ahead concern the following: optimization of management in underdeveloped countries, with reduction of diagnostic and referral-for-care intervals, and the applicability of currently curative regimens; the development of lower intensity but equally effective treatments for frail or immunocompromised patients at risk of death by complications; the identification of very high-risk patients through positron-emission tomography and minimal residual disease assays; and the assessment in these and the few refractory/relapsed ones of new monoclonals (ofatumumab, blinatumomab, inotuzumab ozogamicin) and new molecules targeting c-MYC and key proliferative steps of B-cell malignancies.

show abstract

Section: Minimal Disseminated and Residual Diseasementioning

confidence: 77%

Section: Other Clinical and Biological Risk Factorsmentioning

confidence: 97%

Burkitt lymphoma in adolescents and young adults: management challenges

Dozzo¹,

Carobolante²,

Donisi³

et al. 2016

AHMT

View full text Add to dashboard Cite

show abstract

“…Since 1997, patients with B‐NHL have been enrolled in the NHL‐BFM based, AIEOP LNH‐97 protocol . However, based on the reported inferior outcome of patients with PMLBL compared to other B‐NHL histological subtypes treated in the NHL‐BFM trials (EFS 70% vs. 84%), from 2007 the AIEOP‐NHL committee recommended to treat PMLBL according to a modified version of AIEOP LNH‐97.…”

Section: Methodsmentioning

confidence: 99%

“…Furthermore, all patients received six doses at 375 mg/m 2 of anti‐CD20, rituximab. Central nervous system (CNS) prophylaxis was given according to AIEOP LNH‐97 protocol . Evaluation of response was scheduled after each chemotherapy course until complete remission (CR) was obtained (defined as absence of any residual disease) by performing procedures positive for disease at diagnosis.…”

Section: Methodsmentioning

confidence: 99%

“…The few reports in young patients show an inferior outcome compared with either adults with PMLBL, or children with other B‐NHL histological subtypes, that is, event‐free survival (EFS) rates ranging between 70% and 80% . In 2007, based on the results of the NHL Berlin–Frankfurt–Münster Group (BFM) trial, the ongoing national AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH‐97 protocol was modified with the aim to improve the survival of patients affected by PMLBL. Here, we report the clinical characteristics and outcome of a series of patients treated according to the “AIEOP LNH‐97 guidelines for PMLBL”.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary mediastinal large B‐cell lymphoma: Outcome of a series of pediatric patients treated with high‐dose methotrexate and cytarabine plus anti‐CD20

Pillon

Carraro

Mussolin

et al. 2017

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.

show abstract

Treatment‐related mortality in newly diagnosed pediatric cancer: a population‐based analysis

et al. 2018

View full text Add to dashboard Cite

Using a previously developed reliable and valid treatment‐related mortality (TRM) definition, our objective was to describe the proportion of children newly diagnosed with cancer experiencing TRM and to identify risk factors for TRM in a population‐based cohort. We included children with cancer <19 years diagnosed and treated in Ontario who were diagnosed between 2003 and 2012. Children with cancer were identified using data in a provincial registry. Cumulative incidence of TRM was calculated where progressive disease death was considered a competing event. Among the 5179 children included, 179 had TRM, 478 died of progressive disease, and 4522 were still alive. At 5 years, the cumulative incidence of TRM among the entire cohort was 3.9% (95% confidence interval (CI) 3.3–4.5%). When compared to brain tumor patients, leukemia and lymphoma patients had a significantly higher risk of TRM (hazard ratio (HR) 2.5, 95% CI: 1.6–4.0; P < 0.0001). Infants were at significantly higher risk of TRM across diagnostic groups. Other factors associated with higher risks of TRM were metastatic disease (P < 0.0001), diagnosis prior to 1 January 2008 (P = 0.001), hematopoietic stem cell transplantation (HSCT) (P < 0.0001), and relapse (P < 0.0001). The 5‐year cumulative incidence of TRM was 3.9% among newly diagnosed children with cancer. Infants were at higher risk of TRM across diagnostic groups. Other risk factors for TRM were leukemia or lymphoma, metastatic disease, earlier diagnosis year, HSCT, and relapse. Future work should further refine prognostic factors by specific cancer diagnosis to best understand when and how to intervene to improve outcomes.

show abstract

Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B‐Cell Lymphoma treated with theAIEOP LNH‐97 protocol

Cited by 38 publications

References 25 publications

Burkitt lymphoma in adolescents and young adults: management challenges

Burkitt lymphoma in adolescents and young adults: management challenges

Primary mediastinal large B‐cell lymphoma: Outcome of a series of pediatric patients treated with high‐dose methotrexate and cytarabine plus anti‐CD20

Treatment‐related mortality in newly diagnosed pediatric cancer: a population‐based analysis

Contact Info

Product

Resources

About